News

April 17, 2019April 17, 2019

Anti-Inflammatory Naproxen Fails to Prevent Alzheimer’s Progression, Phase 2 Trial Confirms

News

Treatment with naproxen, an anti-inflammatory medication, failed to prevent the progression of Alzheimer’s in individuals at risk of developing the disease, results from a Phase 2 clinical trial show. ... Read more

April 15, 2019April 15, 2019

Toll of Family Caregiving on Health is Much Smaller Than Previously Reported, Study Suggests

News

While caregiving for people with Alzheimer’s and other disorders has a significant detrimental impact on caregivers’ immune system, the association is weak — less than 1% — and may ... Read more

April 12, 2019April 12, 2019

New Research Unit at England’s University of East Anglia to Study Possible Link Between Sleep and Dementia

News

To enable researchers to study prospective links between sleep and dementia, a cutting-edge sleep unit has opened at the University of East Anglia (UEA) in Norwich, England. While sleeping issues ... Read more

April 10, 2019April 15, 2019

Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant

News

A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the ... Read more

April 8, 2019April 8, 2019

Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds

News

The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from ... Read more

April 5, 2019April 5, 2019

Gantenerumab Continues to Show Promise in Reduction of Amyloid Plaques

News

Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the ... Read more

April 3, 2019April 3, 2019

UB-311 Vaccine Safe in Mild Alzheimer’s Patients, Phase 2a Trial Shows

News

United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer’s disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial ... Read more

April 1, 2019April 1, 2019

Antiviral Medicine Could Help Halt Cognitive Decline in Early Alzheimer’s, Preliminary Data Show

News

Preliminary data from a Phase 2 study suggests that treating early Alzheimer’s disease patients who are positive for herpes simplex virus with an antiviral medicine may help halt their ... Read more

March 29, 2019April 8, 2019

AVP-786 Relieves Agitation in Alzheimer’s Patients, Preliminary Phase 3 Trial Results Show

News

AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer’s dementia, according to preliminary data from a Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate ... Read more

March 27, 2019March 27, 2019

ALZ-101 Vaccine Fares Well in Preclinical Study of Alzheimer’s Fish

News

Alzinova‘s ALZ-101 vaccine — designed to target toxic forms of the amyloid beta protein that drive neurodegeneration in Alzheimer’s disease — was well-tolerated in non-human primates and displayed efficacy in a ... Read more

Pin It on Pinterest